Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience

Cancer

Volumn 97, Issue 9, 2003, Pages 2218-2224

  Lazo, Guillermo ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a   Thomas, Deborah ^a   O'Brien, Susan ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Molecular recurrence; Molecular remission; Nuclear retinoic acid receptor; PML gene

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; BUSULFAN; CELL NUCLEUS RECEPTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; EPIGASTRIC PAIN; FATIGUE; FLUID RETENTION; GENE; GENETIC CODE; HEADACHE; HUMAN; PERIPHERAL NEUROPATHY; PML GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RASH; SIDE EFFECT; THORAX PAIN; DRUG RESISTANCE; FOLLOW UP; GENETICS; MALE; METABOLISM; MIDDLE AGED; REMISSION; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; OXIDES; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037403916     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11314     Document Type: Article

References (32)

1. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8:1913-1921.
2. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
3. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol. 1997;40(Suppl):S25-S29.
4. Tallman MS. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia. 1998;12(Suppl 1):S37-S40.
5. Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994;73:2946-2952.
6. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90:1014-1021.
7. Huang M, Ye Y, Chen S, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
9. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1318.
10. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
11. Estey E, Thall P, Mehta K, et al. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996;87:3650-3654.
12. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991;78:1413-1419.
13. Warrell RP Jr., Frankel SR, Miller WH Jr., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
14. Estey EH, Giles FJ, Kantarjian H, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:2230-2235.
15. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224.
16. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225-2229.
17. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
18. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14:262-270.
19. Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97:264-269.
20. 3 on patients with newly-diagnosed acute promyelocytic leukemia. Proc Am Soc Clin Oncol. 2002;21(1 of 2):262a.
21. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061.
22. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood. 1998;92:1497-1504.
23. Rousselot P, Labaume S, Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999;59:1041-1048.
24. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia. 1998;12:1383-1391.
25. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 1999;455:59-62.
26. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 2000;6:4957-4964.
27. Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol. 2000;27:560-577.
28. Novick SC. Arsenicals in hematologic cancers. Semin Oncol. 2000;27:495-501.
29. Lu M, Levin J, Sulpice E, et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol. 1999;27:845-852.
30. Che-Pin L. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma. 2000;38:195-198.
31. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001;97:1514-1516.
32. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98:266-271.